A comparable molecular profile in non-small cell lung cancer has been linked to PD-L2-mediated immune evasion and an enhanced response to EGFR-tyrosine kinase inhibitor therapy combined with immune checkpoint inhibitors, suggesting that EGFR/CDKN2A co-alterations in OSCC may similarly modulate tumor immunogenicity and warrant further investigation [19]. Here, CDKN2A is linked to non-small cell lung carcinoma.